• Filter by age range:
  • all adults (15-64) |
  • young adults (15–34) |
  • youngest adults (15–24)
• Filter prevalence:
  • lifetime prevalence |
  • last 30 days prevalence |
  • last 12 months prevalence

Statistics found here the series is GPS-5

Category	Title
GPS	GPS-5. Last 12 months prevalence of amphetamines use among young adults aged 15 to 34 and 15 to 24, measured by population surveys
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 12 months prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 12 months prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 12 months prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Last 12 months prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Last 12 months prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Last 12 months prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)